Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.44 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.41 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.41 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.41 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 10/20 | 0.40 |
| ▸ | KDM4A | O75164 | 1/20 | 0.39 |
| ▸ | NQO2 | P16083 | 1/20 | 0.39 |
| ▸ | RPS6KA1 | Q15418 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20049210 | 0.89 | LMNA (0.47) | LMNAPOLBCACNA1HCACNA1BCACNA1C | |
| SCHEMBL21135383 | 0.82 | POLB (0.49) | LMNAPOLBCACNA1HCACNA1BCACNA1C | |
| SCHEMBL29592899 | 0.82 | POLB (0.49) | LMNAPOLBCACNA1HCACNA1BCACNA1C | |
| SCHEMBL20269379 | 0.81 | POLB (0.44) | LMNAPOLBCACNA1HCACNA1BCACNA1C | |
| SCHEMBL20380317 | 0.80 | LMNA (0.59) | LMNAPOLBCACNA1HCACNA1BCACNA1C | |
| SCHEMBL20049741 | 0.80 | PTGS2 (0.50) | PTGS2P2RX7EPHX2 | |
| SCHEMBL29430481 | 0.79 | KCNA5 (0.53) | KCNA5KDM4ANQO2 | |
| SCHEMBL825511 | 0.79 | KCNA5 (0.53) | KCNA5KDM4ANQO2 | |
| SCHEMBL20289154 | 0.76 | POLB (0.40) | LMNAPOLBCACNA1HCACNA1BCACNA1C | |
| SCHEMBL20049678 | 0.76 | NR1H2 (0.45) | LMNAPOLBCACNA1HCACNA1BCACNA1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11207283-B2 | Inactivators of toxoplasma gondii ornithine aminotransferase for treating toxoplasmosis and malaria | NORTHWESTERN UNIVERSITY (US) | 2021-12-28 | — | — | US | disclosed |
| US-20200281880-A1 | INACTIVATORS OF TOXOPLASMA GONDII ORNITHINE AMINOTRANSFERASE FOR TREATING TOXOPLASMOSIS AND MALARIA | NORTHWESTERN UNIVERSITY (US) | 2020-09-10 | — | — | US | disclosed |
| US-10632088-B2 | Inactivators of Toxoplasma gondii ornithine aminotransferase for treating toxoplasmosis and malaria | NORTHWESTERN UNIVERSITY (US) | 2020-04-28 | — | — | US | disclosed |
| US-20180098952-A1 | INACTIVATORS OF TOXOPLASMA GONDII ORNITHINE AMINOTRANSFERASE FOR TREATING TOXOPLASMOSIS AND MALARIA | NORTHWESTERN UNIVERSITY (US) | 2018-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180098952-A1 | INACTIVATORS OF TOXOPLASMA GONDII ORNITHINE AMINOTRANSFERASE FOR TREATING TOXOPLASMOSIS AND MALARIA | OAT, OTC, ABAT | LMNA 4522/4885POLB 872/4885PTGS2 1138/4885 |
| US-11207283-B2 | Inactivators of toxoplasma gondii ornithine aminotransferase for treating toxoplasmosis and malaria | OAT, OTC, ABAT | LMNA 4522/4885POLB 872/4885PTGS2 1138/4885 |
| US-20200281880-A1 | INACTIVATORS OF TOXOPLASMA GONDII ORNITHINE AMINOTRANSFERASE FOR TREATING TOXOPLASMOSIS AND MALARIA | OAT, OTC, ABAT | LMNA 4522/4885POLB 872/4885PTGS2 1138/4885 |
| US-10632088-B2 | Inactivators of Toxoplasma gondii ornithine aminotransferase for treating toxoplasmosis and malaria | OAT, OTC, ABAT | LMNA 4522/4885POLB 872/4885PTGS2 1138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.